Compare Crispr Therapeutics AG (CRSP) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while YieldMax TSLA Option Income Strategy ETF trades at $21.64. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CRSP | TSLY | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $48.25 |
52-Week Low | $44.34 | $20.49 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
TSLY trades at $21.62, down 0.51% today, with a bearish technical outlook per moving averages and mixed oscillators. The ETF maintains high dividend distributions, with recent payouts ranging from $0.21 to $0.52 weekly, but faces capped upside risk due to its option income strategy structure. Recent news highlights concerns over missed Tesla rallies and volatility shifts, impacting sentiment.
Outlook is cautious due to structural limitations in capturing Tesla's gains, with risks including volatility dependency and competitive ETF strategies. The high yield attracts income seekers, but total return potential may be constrained if Tesla appreciates significantly, warranting careful risk assessment for equity-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
